In vitro metabolism of beclomethasone dipropionate, budesonide, ciclesonide, and fluticasone propionate in human lung precision-cut tissue slices

Respiratory Research

Volumn 8, Issue , 2007, Pages

  Nave, Ruediger ^a   Fisher, Robyn ^b   McCracken, Nigel ^a  

^a Nycomed GmbH   (Germany)

^b Vitron Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANE DERIVATIVE; ANTIALLERGIC AGENT; BECLOMETASONE; BUDESONIDE; CICLESONIDE; FLUTICASONE; GLUCOCORTICOID; PREGNANE DERIVATIVE;

ADULT; ARTICLE; CELL SURVIVAL; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; IN VITRO STUDY; LUNG; MALE; METABOLISM; MIDDLE AGED; PHYSIOLOGY;

ADULT; ANDROSTADIENES; ANTI-ALLERGIC AGENTS; BECLOMETHASONE; BUDESONIDE; CELL SURVIVAL; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; MIDDLE AGED; PREGNENEDIONES;

EID: 38449086781     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-8-65     Document Type: Review

References (38)

1. Williams SG, Schmidt DK, Redd SC, Storms W. Key clinical activities for quality asthma care. 2007, http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5206a1.htm
2. Georgitis JW. The 1997 Asthma Management Guidelines and therapeutic issues relating to the treatment of asthma. Chest 1999, 115:210-217. 10.1378/chest.115.1.210, 9925086.
3. Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001, 107:937-944. 10.1067/mai.2001.115653, 11398069.
4. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002, 15:35-50. 10.1006/pupt.2001.0312, 11969362.
5. Pelaia G, Vatrella A, Cuda G, Maselli R, Marsico SA. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases. Life Sci 2003, 72:1549-1561. 10.1016/S0024-3205(02)02446-3, 12551744.
6. Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 1997, 91:22-28. 10.1016/S0954-6111(97)90102-5, 9474364.
7. Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998, 157:S1-S53.
8. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999, 159:941-955. 10.1001/archinte.159.9.941, 10326936.
9. Newman SP. Deposition and effects of inhaled corticosteroids. Clin Pharmacokinet 2003, 42:529-544. 10.2165/00003088-200342060-00003, 12793838.
10. Rohatagi S, Appajosyula S, Derendorf H, Szefler S, Nave R, Zech K, Banerji D. Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004, 44:37-47. 10.1177/0091270003260334, 14681340.
11. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006, 28:1042-1050. 10.1183/09031936.00074905, 17074919.
12. Dent G. Ciclesonide (Byk Gulden). Curr Opin Investig Drugs 2002, 3:78-83.
13. Postma DS, Sevette C, Martinat Y, Schloesser N, Aumann J, Kafé H. Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001, 17:1083-1088. 10.1183/09031936.01.00099701, 11491148.
14. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Effect of inhaled ciclesonide on airway responsiveness to inhaled AMP, the composition of induced sputum and exhaled nitric oxide in patients with mild asthma. Pulm Pharmacol Ther 2001, 14:141-147. 10.1006/pupt.2001.0288, 11273796.
15. Larsen BB, Nielsen LP, Engelstätter R, Steinijans V, Dahl R. Effect of ciclesonide on allergen challenge in subjects with bronchial asthma. Allergy 2003, 58:207-212. 10.1034/j.1398-9995.2003.00052.x, 12653794.
16. Nave R, Fisher R, Zech K. In Vitro metabolism of ciclesonide in human lung and liver precision-cut tissue slices. Biopharm Drug Dispos 2006, 27:197-207. 10.1002/bdd.500, 16566061.
17. Mutch E, Nave R, Zech K, Williams FM. Esterases involved in the hydrolysis of ciclesonide in human tissues. Eur Respir J 2003, 22:267s-268s.
18. K D, R E, A K. Ciclesonide: An on-site-activated steroid. New drugs for asthma, allergy and COPD 2001, 91-93. Basel, Karger, Hansel TT and Barnes PJ.
19. Sato H, Nave R, Nonaka T, Mochizuki T, Takahama S, Kondo S. In vitro metabolism of ciclesonide in human nasal epithelial cells. Biopharm Drug Dispos 2007, 28:43-50. 10.1002/bdd.529, 17117454.
20. Nave R, Hummel RP, Wohlsen A, Herzog R, Zech K. The active metabolite of ciclesonide, des-isobutyryl ciclesonide, forms highly lipophilic fatty acid conjugates in precision-cut rat lung slices. Am J Respir Crit Care Med 2004, 169:A91.
21. Nave R, Meyer W, Fuhst R, Zech K. Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide. Pulm Pharmacol Ther 2005, 18:390-396. 10.1016/j.pupt.2005.02.012, 16179214.
22. Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 1998, 26:623-630.
23. Tunek A, Sjödin K, Hallström G. Reversible formation of fatty acid esters of budesonide, an antiasthma glucocorticoid, in human lung and liver microsomes. Drug Metab Dispos 1997, 25:1311-1317.
24. Würthwein G, Rohdewald P. Activation of beclomethasone dipropionate by hydrolysis to beclomethasone-17-monopropionate. Biopharm Drug Dispos 1990, 11:381-394. 10.1002/bdd.2510110503, 2207292.
25. Fisher RL, Gandolfi AJ, Brendel K. Human liver quality is a dominant factor in the outcome of in vitro studies. Cell Biol Toxicol 2001, 17:179-189. 10.1023/A:1011944531257, 11693579.
26. Fisher RL, Smith MS, Hasal SJ, Hasal KS, Gandolfi AJ, Brendel K. The use of human lung slices in toxicology. Hum Exp Toxicol 1994, 13:466-471.
27. Kricka LJ. Clinical and biochemical applications of luciferases and luciferins. Anal Biochem 1988, 175:14-21. 10.1016/0003-2697(88)90354-5, 3072882.
28. Nave R, Gunawardena KA, Zech K, Bethke TD. Pharmacokinetic disposition of inhaled ciclesonide and its metabolite desisobutyryl-ciclesonide in healthy subjects and patients with asthma are similar. Int J Clin Pharmacol Ther 2006, 44:1-7.
29. Mackie AE, McDowall JE, Falcoz C, Ventresca P, Bye A, Daley-Yates PT. Pharmacokinetics of Fluticasone Propionate inhaled via the Diskhaler® and Diskus® Powder Devices in Healthy Volunteers. Clin Pharmacokinet 2000, 39:23-30. 10.2165/00003088-200039001-00004, 11140430.
30. Van Den Bosch JMM, Westermann CJJ, Aumann J, Edsbäcker S, Tönnesson M, Selroos O. Relationship between lung tissue and blood plasma concentrations of inhaled budesonide. Biopharmaceutics and Drug Disposition 1993, 14:455-459.
31. Esmailpour N, Högger P, Rabe KF, Heitmann U, Nakashima M, Rohdewald P. Distribution of inhaled fluticasone propionate between human lung tissue and serum in vivo. Eur Respir J 1997, 10:1496-1499. 10.1183/09031936.97.10071496, 9230236.
32. Nonaka T, Nave R, McCracken N, Kawashimo A, Katsuura Y. Ciclesonide uptake and metabolism in human alveolar type II epithelial cells (A549). BMC Pharmacol 2007, 7(1):12. 10.1186/1471-2210-7-12, 17900334.
33. Holz O, Zühlke I, Einhaus M, Welker L, Kanniess F, Branscheid D, Nakashima M, Harrison LI, Jörres RA, Richter K, Magnussen H. Direct measurement of BDP and 17-BMP in bronchial and peripheral lung tissue after inhalation of HFA- vs CFC-driven aerosols. Pulmonary Pharmacology and Therapeutics 2004, 17:233-238.
34. Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005, 61:203-208. 10.1007/s00228-005-0910-0, 15824911.
35. Richter K, Kanniess F, Biberger C, Nave R, Magnussen H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005, 45:146-152. 10.1177/0091270004271094, 15647406.
36. Engelstätter R, Escher A, Haefner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J 2005, 26:255s.
37. Chapman KR, Patel P, D'Urzo AD, Alexander M, Mehra S, Oedekoven C, Engelstätter R, Boulet LP. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005, 60:330-337. 10.1111/j.1398-9995.2004.00750.x, 15679718.
38. Mintz S, Alexander M, Li JH, Mayer PV. Once-daily administration of budesonide Turbuhaler was as effective as twice-daily treatment in patients with mild to moderate persistent asthma. J Asthma 2002, 39:203-210. 10.1081/JAS-120002469, 12043851.